Safer drugs, faster!
Side-effect forecast for smarter decisions through Digital Twin technology.

How to help pharmaceutical research to prioritize drug candidates?

We are a techbio startup using AI-powered predictive modeling to evaluate drug side effects of chemical compounds.

Cytocast SCREENER™

Application: From dry lab to wet lab (before new syntheses).
Advantage: Efficiently clusters hundreds to thousands of compounds whilst flagging potential side-effect liabilities, enabling research teams to eliminate weaker candidates earlier in the process.
Benefits: By facilitating rapid 'fail fast' decisions, Cytocast Screener™ significantly reduces time and costs associated with pursuing suboptimal compounds. The platform accelerates early detection by selecting the most promising candidates, providing interactive reports detailing potential side effects, and helping teams focus resources on compounds with the highest probability of success.

Cytocast OPTIMIZER™

Application: During early and late-phase preclinical studies.
Advantage: Refines the choice candidates following in vitro and in vivo testing, enriching the understanding of those selected with adverse event analyses and comparative analyses to support decisions in the preclinical phase. Delivers actionable insights on prioritised candidates, including detailed mechanistic explanations that may underlie predicted side effects. Optionally incorporates secondary pharmacology data to support confident down-selection decisions.
Benefits: This module refines candidate selection following in vitro and in vivo testing by enriching understanding with comprehensive adverse event analyses and comparative assessments. Cytocast Optimizer™ supports evidence-based decision-making in the preclinical phase, helping teams eliminate unworthy candidates before costly late-stage development. Research teams can more confidently focus on the last few candidates in their work of narrowing their selection and defending their project, reducing the time and human energy (money) required to arrive at final selection.

Cytocast NOMINATOR™

Application: To select "lead" and "backup" candidates.
Advantage: Provides sophisticated, fully interactive reports quantifying adverse-event risk profiles with unparalleled depth of final candidates to optimize clinical trial decision-making.
Benefits: Selection includes state-of-the-art, in-depth consideration of the probabilities of advers effects in clinical trials. The completion of the Cytocast exercise makes a major contribution to the prevention of the disastrous outcome for the project. Features optional drug–drug interaction predictions and safety profile comparisons against competing therapies to de-risk lead nomination. Cytocast Nominator™ delivers comprehensive reports and detailed outcome analyses of final candidates, enabling pharmaceutical companies to optimise clinical trial design and execution with greater confidence in candidate selection.

Testimonials

Demo

Interested in our products?

How we do it

Cytocast is using computer simulations to determine the most effective treatment for patients while minimazing potential side effects

0

Proteins per tissue

0

Binding sites per tissue

0

Predictable side effects

0

Regulatory pathways

0

Tissue types

Blog

Press Release: Cytocast Launches Three AI-Powered Products to Predict and Mitigate Drug Side-Effect Risk as Early as in Discovery and Preclinical Development

2025-10-30

Cytocast announced the market entry of three leading-edge products today: Cytocast Screener™, Cytocast Optimizer™, and Cytocast Nominator™ - designed to bring earlier, more interpretable safety insights to drug discovery and preclinical decision-making.

Virtual drug testing: can AI and cell simulations replace lab experiments?

2025-04-02

Using AI and whole-cell simulations, our team at Cytocast is building the next generation of drug discovery tools. The CYTOCAST DIGITAL TWIN Platform™ creates realistic, dynamic models of human cells, capable of simulating billions of molecular interactions per second.

Unraveling COVID-19’s neurological impacts: Insights into microglial dysfunction and CNS inflammation

2025-03-25

A recent study sheds light on the complex molecular and cellular mechanisms underpinning neurological pathologies caused by COVID-19, with a focus on microglial dysfunction and central nervous system (CNS) inflammation.